Category: Uncategorized

A novel benzodiazepine detected after death is not automatically the drug that caused the death. A Victorian study of 140 overdose deaths used a narrower inclusion rule: forensic medical experts had determined that at least one novel benzodiazepine contributed to the fatal outcome. Its changing drug counts describe that selected group, rather than every positive autopsy test or the risk per person using each substance.

How the registry selected the deaths

Schumann, Syrjanen and Dwyer examined the Victorian Overdose Deaths Register for 1 January 2009 through 31 December 2023. Trained coders reviewed deaths reported to the Coroners Court of Victoria. Registry inclusion required forensic medical evidence, including toxicology and autopsy, that acute toxic effects of one or more drugs played a contributory role.

The researchers extracted the contributing novel benzodiazepines and dates of death. They identified 140 deaths: 109 males and 31 females, aged 17–61 years. The earliest was in 2015, with only two before 2019. Annual counts were 10 in 2019, 28 in 2020, 26 in 2021, 40 in 2022 and 34 in 2023.

These were historical Victorian findings. The paper did not supply the number of people exposed to each drug, a living comparison group, or an all-deaths toxicology denominator. Consequently, the counts cannot rank individual drugs by fatal risk.

One death could contribute to several drug counts

Seventy-seven deaths, or 55%, involved one contributing novel benzodiazepine; 63, or 45%, involved multiple novel benzodiazepines. Within the latter group, 48 involved two, seven involved three, four involved four and four involved five.

The most frequently contributing compounds were etizolam in 60 deaths, bromazolam in 39, clonazolam in 34, flualprazolam in 33 and clobromazolam in 21. These overlapping counts must not be added as if they represented different people. A death with two contributing compounds appeared on both corresponding lines in the chronological figure.

The paper also contains an unresolved inconsistency: one results statement says all 140 deaths had a contributing drug outside the novel-benzodiazepine group, while another says 139. That prevents a definitive exact total for this feature from the main report. Either statement makes mixed-drug contribution central to interpretation; neither supports describing the series as 140 isolated benzodiazepine poisonings.

What the temporal clusters showed

The authors visually identified eight groupings, including subgroups. Examples included 39 etizolam-involved deaths from January 2019 through March 2021, 22 flualprazolam-involved deaths from April 2021 through April 2022, and 21 bromazolam-involved deaths from April through December 2023.

Some groupings overlapped in time and drug composition. They were not mutually exclusive categories to sum into a new death total. The investigators expressly acknowledged subjective judgment in choosing the groups; they did not present a formal statistical change-point analysis.

The proposed explanation was a changing unregulated drug supply. That is a hypothesis consistent with the pattern, not direct measurement of the composition of products consumed in every death. The study did not establish an identical national market pattern or show that two co-contributing drugs necessarily came from the same tablet.

What the report cannot tell an individual case reviewer

This registry analysis did not provide one uniform specimen collection site, death-to-collection interval, preservation protocol, concentration dataset or analyte-specific analytical limit. It therefore cannot supply a concentration threshold for fatality or separate antemortem exposure from postmortem concentration change.

Its practical lesson is to preserve the original classification: detection, expert-assessed contribution and a sole causal agent are different claims. The same distinction matters when a single “main intoxicant” category compresses a mixed-drug death. For an individual investigation, the laboratory finding must remain attached to the specimen, analytical evidence, autopsy and circumstances that supported the causal assessment.

Primary source

Schumann JL, Syrjanen R, Dwyer JA. Changes over time in novel benzodiazepines contributing to fatal overdoses in Victoria, Australia. Drug and Alcohol Review. 2025;44:1285–1289. doi:10.1111/dar.14054.

Promising animal findings did not establish a clinically effective methamphetamine treatment. A 2020 review described oxytocin-related reductions in selected methamphetamine-taking and methamphetamine-seeking behaviors in rodents. Its clinical discussion, however, summarized studies involving alcohol, cannabis, cocaine and heroin rather than demonstrating treatment benefit in a methamphetamine-use-disorder trial.

The distinction is between a research rationale and evidence for a particular clinical outcome. This article evaluates what that historical review could support; it does not assess every study published since 2020 or recommend oxytocin treatment.

What kind of evidence did the review assemble?

King, Gano and Becker reviewed preclinical and clinical literature across several substances. This was a narrative review, not a new controlled experiment or a quantitative meta-analysis of methamphetamine trials.

There was no single study population, exposure regimen or pooled methamphetamine treatment effect. Findings came from different species, routes, doses, behavioral procedures and exposure histories. Those differences are part of the evidence rather than details that can be discarded to produce one general claim.

The primary experiments described below are discussed through the review. Their complete original reports were not independently reanalyzed here, and missing cohort or protocol details are not inferred.

Did “less methamphetamine-related behavior” mean one outcome?

No. The review described several distinct experimental endpoints.

Different animal outcomes summarized in the review

Endpoint	What was observed	What it did not independently establish
Self-administration	Responses that produced methamphetamine infusions	Long-term abstinence or clinical recovery
Progressive-ratio responding	Work performed as the response requirement increased	A direct measure of subjective pleasure
Reinstatement	Renewed seeking after responding had been reduced or extinguished	A human relapse rate
Conditioned place preference	Preference associated with a drug-paired environment	Voluntary drug intake or a dependence diagnosis
Locomotion and stereotypy	Movement and repetitive behavior	A comprehensive measure of reward, toxicity or impairment

Agreement across different measures can strengthen a research rationale. It does not make the measures interchangeable or supply clinical outcomes that were never observed.

Which doses and routes were relevant?

The review described systemic oxytocin at 0.3 and 1 mg/kg, administered intraperitoneally, as reducing active-lever responding and methamphetamine infusions in rat self-administration experiments. It also reported reduced responding under a progressive-ratio schedule.

Those numbers are oxytocin pretreatment doses. They are not methamphetamine doses, plasma concentrations or human dosing instructions. The review’s summary does not supply every independent animal denominator, methamphetamine unit dose or timing detail needed to reproduce those experiments.

Other work used direct central administration, including intracerebroventricular oxytocin at 2.5 micrograms in methamphetamine place-preference research. That route places the intervention into the brain’s ventricular system; it cannot be equated with an intranasal spray or a peripheral injection.

The review also described oxytocin given during abstinence: 1 mg/kg intraperitoneally for 15 days within a 30-day abstinence period, followed by reduced methamphetamine-primed reinstatement in male and female rats. This was a repeated pretreatment regimen and an animal seeking endpoint, not a measured human relapse-prevention effect.

Were timing and the trigger for seeking important?

Yes. The reviewed experiments distinguished cues previously paired with drug, a drug prime and stress-related triggers. A finding under one trigger does not prove the same result under all others.

For example, the review described oxytocin pretreatment reducing stress-related increases in prefrontal glutamate during methamphetamine place-preference reinstatement in mice, while not reducing the glutamate increase associated with methamphetamine priming. Preserving that negative comparison prevents a general claim that oxytocin blocked every relevant glutamate response.

Administering an intervention during learning, before a test, repeatedly during abstinence or directly into a selected brain region also asks different causal questions. These regimens cannot be collapsed into a single “oxytocin works” conclusion.

Did the review identify one confirmed mechanism?

No. It discussed interactions involving dopamine, glutamate, stress systems and other signaling pathways. These provided possible explanations for the behavioral findings, with varying levels of experimental support.

The authors also emphasized uncertainty about how peripheral oxytocin influences central signaling. Evidence of brain or cerebrospinal-fluid exposure does not by itself establish delivery to the relevant target at an effective concentration, identify the pathway responsible for behavior, or demonstrate clinical benefit.

Species, sex, local concentration and receptor interactions could change responses. The review’s broader discussion of tolerance and sensitization across substances should not be used to assign the same effect to methamphetamine and amphetamine under every regimen.

Could the human studies fill the methamphetamine evidence gap?

The review’s clinical section described small studies involving other substance-use populations, with outcomes such as craving, withdrawal symptoms, stress responses or cue reactivity. Those outcomes were not equivalent to verified sustained reductions in methamphetamine use.

Nor were the human findings uniformly positive. For example, a cocaine study described reduced desire to use the drug without an effect on cue-induced craving. The review also discussed sex-dependent and nonsignificant findings in cannabis-related stress research.

Evidence from one substance and endpoint can motivate a new trial. It cannot substitute for that trial or establish a benefit in a different population.

What is the defensible conclusion?

The historical review supported further investigation of oxytocin-related signaling in methamphetamine research. It did not establish an effective human methamphetamine treatment, a safe dosing regimen, an individual prognosis or an impairment threshold.

The useful reading discipline is to keep the intervention, route, timing, independent subject count and measured outcome attached to each result. When a review omits necessary details, that gap should limit the claim rather than invite reconstruction.

Scientific source

King CE, Gano A, Becker HC. The Role of Oxytocin in Alcohol and Drug Abuse. Brain Research. 2020;1736:146761. doi:10.1016/j.brainres.2020.146761. Full-text author manuscript. Historical narrative review; the underlying animal and human studies are described through that review rather than presented as independently reviewed primary reports.

A reported intention to use methamphetamine and a clinically classified opioid overdose can coexist without establishing exactly what product was consumed. A 2024 study of San Francisco overdose-response records identified 32 events in which methamphetamine was the reported intended substance and no opioid use was reported as intentional.

The finding raises an important exposure question. It does not, by itself, prove that 32 methamphetamine samples were contaminated with fentanyl, estimate the contamination rate of the local supply, or determine an individual person’s intent.

What kind of study was this?

Bazazi and colleagues retrospectively reviewed consecutive suspected-overdose records from the San Francisco Street Overdose Response Team, covering June through September 2022. The team included community paramedics and peer counselors responding to suspected overdoses, often with other emergency services.

This was a review of medically attended, nonfatal events. It was not a controlled drug-administration experiment, a survey of all methamphetamine users, a fatal-overdose investigation or a systematic chemical analysis of purchased drugs.

The publication date was April 2024, but the observations concerned four months in 2022. They do not establish current drug-market conditions in San Francisco or elsewhere.

How did the denominator change?

From suspected-overdose records to the methamphetamine-intent subgroup

Stage	Reported count	Interpretation
Suspected-overdose response records reviewed	448	Starting record set
Records meeting the study’s opioid-overdose definition	281	Clinical classification from available documentation
Classified events with intended-substance information	171	Complete cases for the main intentionality analysis
No reported intentional opioid use	73	42.7% of the 171 complete cases
Methamphetamine reported as intended	32	43.8% of the 73; 18.7% of the 171

Those percentages answer different questions. Neither 43.8% nor 18.7% is the probability that a methamphetamine product contained fentanyl or that a person using methamphetamine would overdose.

The unit of analysis was a response record or event. The reported totals should not automatically be described as a cohort of that many unique people with independently verified exposures.

How was an opioid overdose classified?

The study’s adapted case definition required a narrative describing suspected overdose or unresponsiveness, naloxone administration by a bystander or emergency personnel, and subsequent improvement in responsiveness or respiratory rate.

The researchers adapted an existing emergency-record classification approach because their clinical-impression information was unstructured. They acknowledged imperfect sensitivity and specificity. Records not meeting the definition could represent another type of event or insufficient documentation, rather than a confirmed absence of overdose.

The case definition did not require a fentanyl-specific laboratory result. It therefore identified a documented clinical pattern, not the exact opioid, dose, product composition or route of unintended exposure.

How was intention determined?

Intended substance use came from patient self-report recorded in paramedic free-text notes. Two researchers independently reviewed batches until achieving more than 95% concordance, after which one reviewer conducted abstraction and the principal investigator checked a random 5% subset.

Concordance described agreement in interpreting the records. It did not independently verify that every recorded account was complete or accurate.

Among the 73 events without reported intentional opioid use, 53 involved an intended stimulant. Methamphetamine accounted for 32, crack cocaine for 11, powder cocaine for eight and an unspecified stimulant for two. These were reported intended substances, not confirmed analytical identifications.

Did the study identify the exposure mechanism?

No. The authors discussed several possibilities: substitution or mistaken identification, contamination of a non-opioid product, storage together, and reuse of equipment previously used for fentanyl. The record review did not distinguish those mechanisms.

Intentional opioid use might also have been underreported. Conversely, uncertainty in self-report does not justify assuming that every report of unintended use was false. The evidence supports preserving the uncertainty rather than selecting one explanation without additional information.

A forensic investigation would need case-specific evidence, such as retained-product testing, biological toxicology, packaging, timing and a fuller exposure history, to evaluate competing explanations. This study did not supply those measurements for each event.

How much information was missing?

Of the 281 events classified as opioid overdoses, 110 lacked intended-substance information. The complete-case percentage of 42.7% therefore cannot simply be applied to all 281, much less all overdoses in the city.

The paper’s discussion contains an arithmetic inconsistency: it gives a hypothetical missing-data estimate as 28% with the fraction 78/281, whereas the main results and table report 73 events without intentional opioid use. Using the reported main-results numerator, 73/281 is approximately 26.0%. That calculation is a hypothetical proportion if every missing-intent event involved intentional opioid use, not a corrected observed prevalence.

The alternative clinical definition added three classified overdoses, but none had intended-substance information, so it did not change the complete-case analysis. Missingness itself remained unresolved.

What should be concluded?

The study documents a meaningful mismatch between reported intended substances and clinical event classification in a selected historical record set. It supports further investigation of unintended opioid exposure among people intending to use stimulants.

It does not establish the frequency of fentanyl contamination in methamphetamine, prove the mechanism of an individual event, or turn a clinical classification into a chemically confirmed dose. Separating intention, clinical response and analytical identification makes the finding more useful and more defensible.

Scientific source

Bazazi AR, Low P, Gomez BO, et al. Overdose from Unintentional Fentanyl Use when Intending to Use a Non-opioid Substance: An Analysis of Medically Attended Opioid Overdose Events. Journal of Urban Health. 2024;101(2):245–251. doi:10.1007/s11524-024-00852-0. Full text. Historical observational review of 2022 emergency-response records; the main-results and discussion numerator discrepancy is identified above.

Even a high-resolution mass spectrometer cannot measure drug that was discarded before injection. During development of a postmortem blood assay, Rosano and colleagues found that a weakly acidic extraction wash lost more than 90% of benzoylecgonine and its labeled internal standard. Changing the wash conditions improved recovery. The observation concerns sample preparation, not disappearance of cocaine exposure from the body.

What method was being developed?

The investigators developed a UPLC–MS^E/time-of-flight method for 16 drugs and metabolites and compared it with a nominal-mass UPLC–MS/MS method. The panel included benzoylecgonine, cocaine, cocaethylene, several opioids and other frequently encountered drugs.

Quantitation used analyte-matched deuterated internal standards added before extraction. Blood underwent mixed-mode solid-phase extraction, washing, elution, evaporation and reconstitution before either instrument analyzed the extract. Every one of those stages preceded the mass measurement.

Why was benzoylecgonine vulnerable to the wash?

Benzoylecgonine has both positively and negatively ionizable groups. The authors reported that a wash at approximately pH 4.5 resulted in loss of more than 90% of benzoylecgonine and its deuterated standard during the methanol wash before the intended elution.

Reducing the wash pH to approximately 1.0 increased benzoylecgonine recovery above 90% in the development discussion. That was a specific change within this cartridge and workflow. It is not a universal instruction for every extraction system, matrix or analyte.

The loss of both analyte and labeled standard is particularly instructive. A standard can help account for matched losses, but it does not physically restore the missing material. A favorable ratio alone cannot demonstrate adequate absolute signal, detection performance or recovery. This inference should be checked against the actual method validation rather than assumed from the presence of an internal standard.

Recovery and ion suppression were tested separately

The validation used drug-negative blood from six donors at 100 and 1,000 ng/mL. Comparing samples fortified before extraction with samples fortified after extraction evaluated extraction recovery. Comparing post-extraction fortified material with neat solution evaluated matrix effects on instrument response.

These comparisons answer different questions. A low result can arise because less analyte reached the instrument or because co-extracted material altered ionization. The authors optimized chromatographic conditions separately to reduce suppression, reporting final suppression or enhancement within 20% of the neat response.

The abstract summarizes extraction recovery as above 60%, while the results discussion describes above 70% for the finalized panel and standards and above 90% for benzoylecgonine. These are reported summaries from the paper, not a basis for assigning one exact recovery percentage to every case specimen.

What quantitative performance was demonstrated?

The final method used a 25–3,000 ng/mL calibration range, a 25 ng/mL lower quantitation limit and an administratively selected 10 ng/mL detection threshold evaluated over 12 batches. Precision and bias were assessed with 16 replicate control measurements at 40, 125, 1,600 and 2,500 ng/mL. Both compared methods met the study’s CV below 15% and bias below 20% criteria, despite greater high-resolution variation for some analytes and levels.

Casework comparison involved discarded, de-identified extracts from 159 medical examiner cases. Because both instruments examined prepared extracts, agreement between them could not independently test whether a shared earlier preparation step had lost material. The study’s separate extraction experiments were therefore essential evidence.

The paper does not report one uniform blood collection site, death-to-collection interval or decomposition category for those 159 cases. Its method-development wash experiment was not an in-body stability study.

What records matter when reviewing a negative result?

Determine the analyte, extraction version, matrix, internal-standard response, recovery evidence and reporting threshold. This study demonstrates a preparation vulnerability discovered and addressed during development; it does not prove that any particular laboratory’s negative case result was wrong.

Nor does a benzoylecgonine concentration alone determine when cocaine was used, whether someone was impaired or what caused death. The extraction question complements the separate problem of drug identity when compounds share an exact mass. It also explains why validation using relevant specimens must extend beyond an instrument’s nominal capability.

Primary source

Rosano TG, Na S, Ihenetu K, Swift TA, Wood M. Multi-drug and Metabolite Quantification in Postmortem Blood by Liquid Chromatography–High-Resolution Mass Spectrometry: Comparison with Nominal Mass Technology. Journal of Analytical Toxicology. 2014;38:495–506. doi:10.1093/jat/bku066.

A blood–urine comparison from living people cannot establish how xylazine behaves after death. A 2025 Ankara study reported xylazine in urine from 28 people and in blood from seven, but expressly included no autopsy cases. Its useful analytical findings do not validate a postmortem conversion, redistribution factor or lethal concentration.

Which population was actually examined?

Erol Öztürk and colleagues examined blood and urine submitted for forensic testing from suspected drug users during January–December 2024. The paper refers to 9,123 cases or biological submissions and identifies 28 xylazine-positive cases, approximately 0.3%. These were living individuals under law-enforcement supervision, not a series of overdose deaths.

The selected regional population cannot establish national prevalence or a person’s probability of poisoning. One discussion passage prints 0.003%; that conflicts with 28 of 9,123 and the paper’s principal 0.3% result. The smaller printed percentage should not be repeated as a second estimate.

Samples were stored at −20°C. The report does not provide a uniform exposure-to-collection interval or a postmortem anatomical collection site. Those missing details cannot be supplied by assuming that every sample represented the same stage after use.

Detection differed between matrices

The results section reports urine xylazine in all 28 positive cases, ranging from 0.7 to 23.1 ng/mL, and blood xylazine in seven, ranging from 0.5 to 1.1 ng/mL. It reports urinary 4-hydroxyxylazine in 22 and 2,6-dimethylaniline in seven. These are different targets and denominators.

These counts do not supply a validated blood-to-urine equation. The absence of a reported blood detection should also remain distinct from proof that no exposure occurred.

Other substances were frequently detected, but not all findings established simultaneous administration or a mixed product. The investigators lacked route and intent information and stated that investigated seized materials had not demonstrated xylazine adulteration. Biological co-detection alone could not prove a particular drug supply composition.

The limits were analyte- and matrix-specific

The method used solid-phase extraction and LC–high-resolution MS with reference standards and xylazine-d6 internal standard. Table 2 reports the following detection and quantitation limits, respectively: xylazine blood 0.025/0.068 ng/mL and urine 0.05/0.12; 2,6-dimethylaniline blood 0.04/0.11 and urine 0.06/0.19; 4-hydroxyxylazine blood 0.025/0.071 and urine 0.05/0.14.

The calibration series began at 0.05 ng/mL and extended to 100 ng/mL. Inclusion of a low calibrator did not make every analyte quantitatively reliable at that level: the stated quantitation limits were higher. The abstract’s description of analytical-limit ranges is less clear than Table 2, so the explicit table values matter.

Precision and bias were tested at 0.5, 25 and 75 ng/mL with eight replicates; the reported results were within the authors’ 15% criteria. Blood recovery ranged from 72.1–98.4% and urine recovery from 70.3–93.4% across the tested analytes and levels. These laboratory recoveries are not percentages surviving in a body after death.

Short handling tests were not a decomposition experiment

Fortified blood and urine were assessed after 72 hours in an 8°C autosampler, five days at 4°C, and the described five-day freeze/thaw evaluation at −20°C. Peak-area comparisons met the stated ±10% acceptance criterion.

Those conditions do not validate stability through decomposition, a long death-to-autopsy interval or every storage duration. The experiment did not measure postmortem formation, redistribution or tissue release. The authors also could not interpret the observed concentrations against a documented clinical course.

What follows for a death investigation?

The study supports retaining the exact matrix, target and analytical threshold when discussing xylazine findings. It does not show that urine and blood are interchangeable or that their ratio dates use. Detection supplies no automatic impairment or cause-of-death conclusion.

Before applying any published method to autopsy material, establish the laboratory’s validation for the actual specimen and condition. Related distinctions appear in matrix-specific calibration bias and the scope of negative autopsy screens.

Primary source

Erol Öztürk Y, Yeter O, Aslıyüksek H, Oztuna A, Sezigen S, Demirel G. The first report from Ankara on the presence of xylazine abuse in blood and urine samples using a validated LC-HRMS method. International Journal of Legal Medicine. 2025;139:2695–2705. doi:10.1007/s00414-025-03562-7.

Cocaine did not simply decline between early postmortem sampling and autopsy. Hearn and colleagues reported different directions of change across blood collection sites, including increases in some femoral samples and decreases in most of the small subclavian subset. Neither a universal degradation correction nor a universal redistribution multiplier described these observations.

Early sampling was still postmortem sampling

The investigators selected medical examiner cases in which circumstances suggested cocaine use. Blood obtained during the initial investigation was compared with later autopsy specimens. “Scene” blood was not a controlled sample collected during life; some intervals were measured from discovery because the time of death was unknown.

The report presents seven detailed cases and overlapping site-specific subsets: six heart comparisons, six femoral comparisons and four subclavian comparisons. These should not be added together as 16 independent deaths or described as seven observations for every site. Not every case had the same specimens.

Scene specimens were collected in tubes containing sodium fluoride and potassium oxalate and refrigerated for transport. Autopsy specimens received the same preservatives and were refrigerated after the examination. These measures addressed handling after collection; they could not prevent changes that had already occurred within the body.

What did the paired site results show?

In the six heart comparisons, three autopsy concentrations were approximately 33–275% higher; the other three remained essentially unchanged. Scene-to-autopsy intervals were approximately 5–20 hours. In the six femoral comparisons, five rose approximately 22.5–117%, while the lowest initial result decreased from 0.10 to 0.06 mg/L over 21 hours.

In three of four subclavian comparisons, concentrations were approximately 15–48% lower at autopsy after 7–20 hours. The fourth increased from 3.0 to 5.0 mg/L after five hours. These were descriptive small-subset observations, not a statistically validated predictor for a new death. Time alone did not consistently explain the direction or size of change.

One case illustrated the opposing patterns particularly clearly: subclavian cocaine decreased from 2.3 to 1.2 mg/L, while femoral cocaine increased from 1.8 to 3.9 mg/L over a reported 20-hour sampling interval. Choosing only one of those trajectories would misrepresent the case.

Aorta comparisons combined site and time

Five comparisons placed later aorta blood against earlier blood from another site. Later values were higher, but these were not paired aorta collections. They could not isolate a change over time from a difference between vessels. The paper also contains a collection-label inconsistency in its first case: prose describes the later peripheral specimen as femoral, while the table labels it iliac.

The authors considered release from tissue stores and hydrolysis competing explanations. They also acknowledged possible initial site differences and the possibility that a second femoral collection drew blood that had moved from more central vessels. The study did not directly quantify each mechanism’s contribution.

What analytical evidence supported the comparison?

Screening and preliminary identification used several techniques. Cocaine and benzoylecgonine quantitation used GC–MS with deuterated internal standards. Samples from each case were analyzed in the same batch and results were means of duplicate measurements.

The paper reported a linear range of 0.02–10.0 mg/L, with coefficients of variation of 6.9% for cocaine and 7.2% for benzoylecgonine. It did not provide a modern, complete validation dataset establishing a separate uncertainty for every specimen. In one case the small benzoylecgonine differences were explicitly discussed against method variation, rather than automatically interpreted as biological change.

What can the study establish in case review?

A collection site’s reputation as “peripheral” does not guarantee that a later concentration remained unchanged. Conversely, a stable pair does not prove that no competing processes occurred. Exact vessel, collection technique, preservation, timing and the distinction between death and discovery need to accompany a reported result.

The study does not reconstruct an individual’s premortem concentration, impairment or cause of death from an autopsy number alone. Compare the separate problem of unmatched cocaine group averages and the broader evidence from sequential postmortem sampling.

Primary source

Hearn WL, Keran EE, Wei H, Hime G. Site-Dependent Postmortem Changes in Blood Cocaine Concentrations. Journal of Forensic Sciences. 1991;36(3):673–684. doi:10.1520/JFS13076J.

Tolerance to one stimulant response does not establish tolerance to another stimulant, even when both act at the dopamine transporter. A 2011 rat study found reduced cocaine-induced dopamine effects after cocaine self-administration, while amphetamine retained activity on the measured endpoints.

The experiment separates responses to two drugs under specific exposure conditions. It does not establish that a person tolerant to cocaine is safe to take amphetamine, or that an unchanged laboratory response means unchanged impairment.

What exposure histories were compared?

Ferris and colleagues used male Sprague-Dawley rats weighing 375–400 g. Cocaine was self-administered intravenously at 1.5 mg/kg per injection under a fixed-ratio-one schedule, meaning one lever press produced an injection. Sessions ended after 40 injections, with five consecutive daily sessions used for the principal comparisons.

As animals completed sessions more quickly, their rate of intake increased. The imposed limit of 40 injections remained distinct from the time required to obtain them; a faster session did not mean an unlimited increase in daily injection count.

A separate group self-administered amphetamine at 0.56 mg/kg per intravenous infusion for five hours per day over five days. Investigators selected that dose to produce dopamine elevations approximately comparable to, or greater than, those associated with cocaine. This was an attempt to compare substantial dopaminergic exposure, not proof that every aspect of the regimens was matched.

Which measurements were made?

Microdialysis measured extracellular dopamine in the nucleus accumbens core of freely moving rats. Separate fast-scan cyclic-voltammetry experiments used isolated brain slices to examine electrically evoked dopamine signals and model release and uptake.

The slice experiments applied cocaine or amphetamine in the bathing solution. The methods give cocaine concentrations of 0.03–30 micromolar and amphetamine concentrations of 0.1–10 micromolar. These are experimental bath concentrations, not blood concentrations, and they cannot supply a human forensic cutoff.

Different analyses had different animal denominators. For example, baseline microdialysis comparisons reported five cocaine-exposed animals and six naive controls; the early slice time-course comparisons reported five animals after one cocaine session and four after three sessions. Repeated samples and concentration steps did not increase the number of independent animals.

What changed after cocaine self-administration?

A cocaine challenge produced a much smaller extracellular dopamine response in cocaine-experienced animals than in naive controls. In slices, cocaine was also less effective at inhibiting dopamine uptake.

The model’s apparent Km parameter summarized uptake inhibition under the assay conditions. Following five cocaine sessions, the maximal reported apparent Km was 7.37 ± 1.38 micromolar, compared with 28.75 ± 3.14 micromolar in naive animals. These were model-derived dopamine-uptake parameters, not measured cocaine concentrations in the rats.

A reduced cocaine effect appeared after one session and remained after the longer exposure histories. The study also found that changes in maximal baseline uptake rate followed a different time course. Reduced sensitivity to cocaine was therefore not simply interchangeable with faster or slower ordinary dopamine clearance.

Was amphetamine similarly blunted?

No corresponding reduction was detected on the studied amphetamine endpoints. After cocaine self-administration, amphetamine retained its ability to affect uptake in slices, and a 0.56 mg/kg intravenous amphetamine challenge still increased extracellular dopamine.

Conversely, after amphetamine self-administration, both cocaine- and amphetamine-related transporter responses remained present without the cocaine-specific reduction produced by the cocaine regimen. This comparison argued against attributing the adaptation solely to a history of elevated extracellular dopamine.

The appropriate wording is that the selected amphetamine responses were preserved under these conditions. A nonsignificant group difference does not independently prove exact equivalence, and the study did not assess every amphetamine effect, dose or exposure pattern.

Did the cocaine-related change persist indefinitely?

No. Slice experiments after five cocaine sessions found reduced cocaine uptake inhibition at one and three days of withdrawal, but a return toward control values by 14 days.

That is an animal assay time course, not an individual human recovery schedule. The return of one transporter-related measure does not establish recovery of mood, cognition, cardiovascular function or all other consequences of repeated exposure.

Why does the paper’s timing require caution?

The microdialysis methods describe testing approximately 48 hours after the final self-administration session, whereas the initial results paragraph describes a comparison less than 24 hours afterward. Those descriptions should not be silently reconciled into a precise single sampling interval.

The slice methods describe testing around 18 hours after the final session, apart from the planned recovery experiments. Microdialysis and slice measurements thus should not be treated as simultaneous observations from one uniform post-dose window.

Does this prove a structural change in the transporter?

No. The authors proposed possible changes in transporter conformation, chemical modification or interactions among transporter proteins. The experiments demonstrated functional differences but did not identify one molecular mechanism as the cause.

They also did not measure subjective euphoria or establish that transporter adaptation alone caused faster cocaine intake. The paper explicitly considered the difficulty of linking the rapid laboratory change to later behavioral escalation.

The practical lesson is specificity: identify which drug, exposure history, specimen or preparation, timing and endpoint support a tolerance claim. A history of tolerance to one stimulant cannot replace evidence about an individual’s response to another.

Scientific source

Ferris MJ, Mateo Y, Roberts DCS, Jones SR. Cocaine-insensitive dopamine transporters with intact substrate transport produced by self-administration. Biological Psychiatry. 2011;69(3):201–207. doi:10.1016/j.biopsych.2010.06.026. Full-text author manuscript. Historical original rat experiments using in vivo microdialysis and ex vivo brain slices.

A genetic manipulation that changes a mouse’s response to methamphetamine can identify a research pathway without establishing a human risk test. A study published in 2024 examined cannabinoid CB2-receptor dysfunction using two mouse models. Findings differed by genetic model, drug regimen and behavioral endpoint.

The paper used “schizophrenia-like” and “psychosis-related” descriptions for selected animal behaviors. No human participants were studied, and the experiments did not diagnose schizophrenia or directly observe human hallucinations.

Which genetic models were compared?

Canseco-Alba and colleagues studied male mice aged seven to nine weeks, weighing approximately 20–25 g. One model had a heterozygous disruption of Cnr2, the gene encoding CB2 receptors. The other, DAT-Cnr2 conditional knockout mice, lacked CB2 receptors in targeted dopamine neurons.

These are different manipulations. A partial whole-organism gene disruption and a cell-targeted deletion cannot be treated as equivalent exposures or pooled into one genotype.

The conditional-knockout mice also had baseline behavioral differences, including increased activity. A post-drug difference therefore needs to be interpreted alongside the pre-existing phenotype, rather than automatically attributed entirely to the acute drug effect.

What did “reverse tolerance” mean?

The investigators used the term for sensitization: an increased selected response after repeated exposure, rather than the reduced response usually described as tolerance.

The induction regimen was methamphetamine at 2 mg/kg intraperitoneally once daily for four days. One week later, the challenge dose was 0.5 mg/kg intraperitoneally. Saline-pretreated and saline-challenged conditions helped distinguish exposure history from the final challenge.

These are administered doses, not measured blood or brain concentrations. The study did not establish a concentration threshold for sensitization, psychosis or functional impairment in a person.

Did both models show greater locomotor sensitization than controls?

Not uniformly. After the repeated regimen, heterozygous mice showed greater locomotor activity than their wild-type comparison group. The locomotor methods report 17 wild-type and 11 heterozygous animals in the repeated-exposure conditions, with smaller saline groups.

In the dopamine-neuron conditional-knockout experiment, both genotypes developed an increased response after the regimen. The conditional-knockout group’s apparent additional increase over wild type did not reach significance.

That null comparison matters. Demonstrating sensitization within both genotypes does not establish that one genotype sensitized more strongly than the other.

Why could high-dose methamphetamine reduce distance traveled?

A separate acute experiment tested saline and methamphetamine doses of 1, 3 and 10 mg/kg intraperitoneally, with ten mice per dose-and-genotype group and 20 minutes of open-field observation.

Responses were not a simple progression toward more distance at every higher dose. At 10 mg/kg, conditional-knockout mice showed reduced distance but increased stereotypic counts. Repetitive behaviors such as sniffing, licking or grooming can occupy time without producing travel through the arena.

Less distance therefore did not mean absence of a drug effect or necessarily less overall behavioral disturbance. Distance and repetitive-movement counts described different dimensions of the response.

What did prepulse inhibition show?

Prepulse inhibition, or PPI, measures how a weaker sound changes the startle response to a subsequent louder sound. It is a sensorimotor-gating assay, not a disorder-specific diagnostic test.

In the heterozygous model, saline conditions, an acute low-dose challenge after saline pretreatment, and repeated methamphetamine followed by saline did not show significant genotype differences in PPI. After the full repeated-exposure-plus-challenge regimen, the overall genotype comparison was significant.

The methods report 16 wild-type and 22 heterozygous mice for that final condition. However, post hoc comparisons at each individual prepulse sound level were not significant. Reporting a difference at every sound intensity would go beyond the results.

The conditional-knockout model also showed reduced PPI under basal conditions. That finding was not itself evidence of a newly induced methamphetamine effect.

Did social behavior prove psychosis?

No. The researchers assessed time spent investigating another mouse versus a non-social alternative and reported reduced social preference in the genetically altered models under basal conditions.

Social preference, activity, repetitive movements and PPI can contribute to an experimental model. None alone establishes that an animal has the full clinical syndrome of schizophrenia, and their combination does not supply an individual human diagnosis.

What remains uncertain about translation?

The experiments used only males, genetically engineered strains and injected methamphetamine. They did not compare human CNR2 variants prospectively, estimate a person’s probability of psychosis or test a CB2-directed treatment in patients.

The authors proposed CB2 signaling as a potential therapeutic research target. A genetic association or knockout phenotype does not establish that activating a receptor will safely reverse the phenotype, and the study did not demonstrate a clinical treatment benefit.

The evidence supports an endpoint-specific role for CB2-related biology in these mouse responses. Keeping the two models, baseline differences and nonsignificant comparisons visible prevents that conclusion from expanding into an unsupported human genetic-risk or treatment claim.

Scientific source

Canseco-Alba A, et al. Cannabinoid CB2 receptors and hypersensitivity to methamphetamine: vulnerability to schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2024;130:110924; electronically published December 20, 2023. doi:10.1016/j.pnpbp.2023.110924. Full-text author manuscript. Original genetic mouse experiments; findings are historical experimental evidence, not a current clinical recommendation.

Movement and a putative affective response to amphetamine need not change together. A study of 30 male rats measured both locomotion and ultrasonic vocalizations after repeated amphetamine exposure. The two outcomes had different predictors and sometimes moved in opposite directions.

The experiment helps separate behavioral endpoints. It did not directly measure subjective pleasure, diagnose dependence or establish that more activity means a drug is more rewarding.

Which animals and exposures were studied?

Garcia and Cain obtained male Sprague-Dawley rats at 30 days of age and began testing after ten days of handling. Animals first completed tests of movement in an unavoidable novel environment, preference for a novel compartment, and vocalizations elicited by experimenter-administered tickling.

They were then block-randomized into saline, 0.3 mg/kg d-amphetamine sulfate, or 1.0 mg/kg d-amphetamine sulfate groups, with ten rats per group. Drug was injected intraperitoneally. Seven treatment exposures occurred over 14 days, followed by a 14-day drug-free interval.

At challenge, previously amphetamine-treated rats received their prior dose, while the ten saline-treated rats were divided between the two amphetamine doses. The newly exposed comparison groups therefore contained five animals per dose.

What did the vocalization measure mean?

The researchers distinguished call types by frequency and shape. The principal reported outcome was frequency-modulated 50-kHz calling, operationally classified within a 35–100-kHz range and with at least three frequency modulations.

A blinded scorer assessed call shape, and approximately 3–5% of calls fell outside the classified frequency ranges. More than 30,000 calls were examined, but those calls came from 30 animals; they were not 30,000 independent subjects.

Prior literature linked such calls to rewarding or positive-affect contexts. That makes them a useful indirect marker, not a verbal account of a rat’s experience. The study did not equate a particular call count with a measured amount of euphoria.

Were calling and locomotion observed at the same time?

No. Vocalizations were recorded for two minutes, 15–17 minutes after injection. Animals then moved to activity chambers for 60 minutes of locomotor recording.

Calls were recorded on the first and seventh treatment exposures and at challenge, rather than throughout every treatment day. Thus, the results compare selected windows and different settings; they do not describe continuous simultaneous tracking of mood and movement.

What happened during repeated amphetamine exposure?

Both amphetamine doses increased locomotion relative to saline, with the higher dose producing greater movement. From the first to the seventh session, the high-dose group increased locomotion but decreased frequency-modulated calling. The low-dose group did not show the same significant within-group changes.

That divergence is the key observation: increased motor output did not imply increased calling. Conversely, fewer calls did not establish reduced concentration, global tolerance or absence of other drug effects.

In regression comparisons with saline at the seventh session, the dose-related reductions in calling were not significant. The high-dose group’s significant within-group decline and its nonsignificant comparison with saline address different questions and should both be retained.

What did the baseline screens predict?

Novelty preference negatively predicted locomotion during the first treatment session: rats preferring the novel compartment more strongly tended to travel less. That relationship did not remain a significant predictor during later treatment.

Tickling-related calling predicted later calling more consistently, while not predicting locomotion. The relationship between that baseline calling screen and treatment-session calling also depended on response to unavoidable novelty, particularly after repeated high-dose exposure.

These were statistical relationships in a small sample, with multiple regressions and interaction tests. They were not externally validated individual prediction rules or proof that novelty response caused a particular drug experience.

Was lasting locomotor sensitization established at challenge?

Not against the newly exposed comparison animals. After the 14-day break, previously amphetamine-treated rats did not move significantly more than formerly saline-treated rats receiving the same challenge dose for the first time.

The authors explicitly acknowledged that “true” locomotor sensitization was not demonstrated by that comparison, despite the high-dose increase between the first and seventh treatment sessions. The small five-animal acute challenge groups limited precision.

Preserving this null comparison prevents the within-treatment increase from becoming an unqualified claim of persistent sensitization.

Could context have influenced the calls?

Saline-treated animals produced unusually high call counts relative to some prior studies—approximately 254 and 283 calls on the first and seventh sessions. The authors considered whether contextual cues associated with tickling carried over despite attempts to distinguish the environments.

That explanation was plausible but unproven. It also illustrates why calling cannot simply be attributed to drug reward without considering learning, anticipation and the recording context.

What does this mean for interpreting stimulant behavior?

Activity, vocalizations, drug seeking and subjective human effects are different endpoints. This study measured the first two and explored their predictors; it did not measure voluntary amphetamine intake or escalation to compulsive use.

The authors’ suggestions about faster tolerance or later escalation in some novelty-responsive animals were hypotheses. They cannot establish an individual’s addiction risk, safety or impairment. The useful conclusion is that visible activation alone does not characterize every dimension of a stimulant response.

Scientific source

Garcia EJ, Cain ME. Novelty response and 50 kHz ultrasonic vocalizations: Differential prediction of locomotor and affective response to amphetamine in Sprague-Dawley rats. Psychopharmacology. 2016;233(4):625–637. doi:10.1007/s00213-015-4132-6. Full-text author manuscript. Historical original rat experiment.

A larger motor response to a drug after exposure to another drug is a defined experimental finding, not a clinical diagnosis. A 2011 study reported cross-sensitization between amphetamine and methylphenidate in female rats. Its findings concern injected exposures and open-field activity under one protocol.

They do not establish that prescribed stimulant treatment causes later substance dependence, predict an individual’s response, or quantify impairment.

Which animals and doses were studied?

Yang, Atkins and Dafny used 50 adult female Sprague-Dawley rats, approximately 180–190 g at entry. The groups included eight saline controls, eight methylphenidate-treated animals, two eight-animal amphetamine groups assigned to different later challenges, and 18 MDMA-treated animals.

The doses were 0.6 mg/kg amphetamine, 2.5 mg/kg methylphenidate and 5 mg/kg MDMA, calculated as free base and injected intraperitoneally in the morning. These were not oral therapeutic exposures, and the drugs were not shown to be equipotent simply because the same testing apparatus was used.

Experiments began on proestrus according to the methods. Starting at a selected cycle stage did not hold hormonal state constant across every subsequent testing day.

How was sensitization tested?

After saline baseline testing on day one, animals received their assigned drug on days two through seven. Following three drug-free days, the original drug was given again on day 11. A different stimulant challenge followed on day 12.

Infrared sensors recorded horizontal activity, distance traveled, rearing and an automated index of repetitive movements. Data were summarized in ten-minute intervals and as totals across two hours.

Sensitization meant increased response to the same drug after repeated exposure. Cross-sensitization meant a greater response to a different challenge drug compared with the response in initially drug-naive animals. These measures are distinct from drug self-administration, craving reports or a longitudinal diagnosis.

What happened with amphetamine and methylphenidate?

Both drugs increased activity acutely. After the drug-free interval, rechallenge produced increased responses consistent with behavioral sensitization, although the specific result depended on the activity index and time summary.

Prior amphetamine exposure was associated with a greater response to methylphenidate in three of four reported motor indices. Prior methylphenidate exposure was associated with a greater response to amphetamine in all four indices. The authors interpreted the reciprocal pattern as cross-sensitization.

The earlier consecutive-dose comparison was less uniform. Methylphenidate showed no significant change between its first and sixth daily administrations. Amphetamine changes appeared in selected time intervals even when the two-hour totals obscured them. The observation window therefore affected whether adaptation was visible.

Why did the MDMA comparison require extra caution?

The 18-animal MDMA group did not show a significant aggregate change on rechallenge relative to the initial exposure. The investigators then examined animals separately and described eight as showing sensitization and ten as showing tolerance.

Those post hoc individual classifications should not be mistaken for independently established biological subtypes or population rates. Minute-by-minute measurements within one rat are not equivalent to additional independent animals.

The paper broadly concluded that MDMA and amphetamine did not cross-sensitize. Its detailed results nevertheless reported increased rearing after amphetamine challenge in the subgroup classified as MDMA-sensitized, with no corresponding significant differences in the other three indices. The subgroup classified as MDMA-tolerant showed no significant challenge differences.

Preserving that endpoint-specific exception is more accurate than saying that every amphetamine response after MDMA was unchanged. Likewise, nonsignificance does not prove exact equivalence.

Did the experiment identify the shared mechanism?

No direct neurotransmitter, receptor, gene-expression or drug-concentration measurements were reported for these behavioral comparisons. The authors discussed dopamine and other pathways as possible explanations.

Reciprocal cross-sensitization is consistent with overlapping adaptation, but does not by itself identify a unique shared pathway or prove that the drugs act identically. Differences in dose, route, timing and motor patterns remain relevant.

Why does this not establish human dependence risk from treatment?

The experiment used adult female rats, injected free-base-equivalent doses and short-term activity measurements. It did not study children with ADHD, compare prescribed oral treatment with no treatment, or follow later human substance-use outcomes.

The paper’s broader concerns about dependence were interpretations of an experimental marker. A clinical causal claim requires evidence addressing the clinical exposure and outcome, including baseline differences and other reasons people receive treatment.

The defensible conclusion is that prior stimulant exposure changed selected later motor responses under this protocol. That result can inform mechanistic research while remaining separate from claims about human diagnosis, treatment causation or individual impairment.

Scientific source

Yang PB, Atkins KD, Dafny N. Behavioral sensitization and cross-sensitization between methylphenidate amphetamine, and 3-4, methylenedioxymethamphetamine (MDMA) in female SD rats. European Journal of Pharmacology. 2011;661:72–85. doi:10.1016/j.ejphar.2011.04.035. Full-text author manuscript. Historical original rat experiment.